Frazier-Backed Mavupharma Scores $20M to Fund STING Program Post author:Sam Post published:November 28, 2017 Post category:BioPharma The Series A funding will be used primarily to advance Mavu’s lead drug candidates into the clinic. Source: BioSpace You Might Also Like Meet the Former Pfizer Husband-and-Wife Team Who Founded Biotech TransPharm January 14, 2018 These 2 New Drugs Make Celgene an Even Bigger Biotech Powerhouse January 26, 2017 Billionaire Businessman Looking to Take Stake in Debt-Ridden Teva November 5, 2017